Coinbase CEO's anti-aging startup NewLimit is raising $435 million, tripling its valuation
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year
Overview
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
